RxDoctor Payments Data

Mridula Reddy, MD

Hematology & Oncology · Middletown, OHNPI 1568649408

Payments from drug & device makers

$3,495in general payments, 2019–2025

Across 185 payments — averaging $18.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$310
  • Eisai Inc.$284
  • Johnson & Johnson$269
  • Pharmacyclics LLC, An Abbvie Company$261
  • Amgen$233
  • E.r. Squibb & Sons, L.L.C.$209
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$2,93184%
  • Education$56416%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,495 in reported general payments places this provider in the 40th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$73,006
Medicare patients
212
Services billed
679

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib14$257,060
EliquisApixaban46$36,046
Abiraterone Acetate15$17,801
XareltoRivaroxaban15$9,429
Anastrozole111$2,145
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen37$1,643
Fentanyl14$1,299
Letrozole13$1,028
Dexamethasone41$666
Hydroxyurea20$527
Warfarin Sodium66$328
Ondansetron OdtOndansetron36$323
Morphine Sulfate ErMorphine Sulfate11$181
Alendronate Sodium25$165
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen12$159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$261$257,06014 claims
PfizerEliquis$58$36,04646 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$24$17,80115 claims
Johnson & JohnsonXarelto$269$9,42915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Middletown

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →